RYR2 and catecholaminergic polymorphic ventricular tachycardia: Although several reports have demonstrated pharmacological rescue of mutant RyR2 function in human CPVT iPSC-CMs (Itzhaki et al., 2012; Jung et al., 2012; Di Pasquale et al., 2013; Zhang et al., 2013), few studies directly correlate in vitro patient-specific drug response differentials to in vivo clinical data.